Imagine a future where Alzheimer's disease is not a looming threat, but a manageable condition. This future might be closer than we think. A groundbreaking new drug developed at Northwestern University, called NU-9, is showing incredible promise in the fight against Alzheimer's, potentially even before memory loss begins. This isn't just about slowing the disease; it's about stopping it in its tracks.
In a recent study, scientists pinpointed a previously unknown, highly toxic subtype of amyloid beta oligomers – essentially, toxic clumps of proteins – that seem to trigger the earliest changes in the brain associated with Alzheimer's. These changes include neuronal dysfunction, inflammation, and the activation of immune cells.
But here's where it gets exciting: NU-9, a small-molecule compound, has been shown to decrease this specific toxic subtype of amyloid beta oligomers. This, in turn, dramatically reduced the damage they cause in a mouse model of Alzheimer's. The researchers are hopeful that by addressing these changes early on, NU-9 could prevent or significantly delay the cascade of events that ultimately destroy brain cells.
This discovery points towards a new strategy for tackling Alzheimer's in its earliest stages, before the debilitating symptoms take hold. The study, which will be published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association on December 18th, could revolutionize how we approach this devastating disease.
"Alzheimer's disease begins decades before symptoms appear," explains Daniel Kranz, the study's first author. "By the time symptoms emerge, the underlying pathology is already advanced. This is likely a major reason many clinical trials have failed. They start far too late. In our study, we administered NU-9 before symptom onset, modeling this early, pre-symptomatic window."
Kranz, a recent Ph.D. graduate, worked alongside William Klein, an expert in Alzheimer's disease and a cofounder of Acumen Pharmaceuticals, which is currently running clinical trials for a therapeutic monoclonal antibody targeting the same subtype of amyloid beta oligomers identified in the study. Richard Silverman, who previously invented pregabalin (Lyrica) to treat fibromyalgia, nerve pain and epilepsy, invented NU-9. Silverman is also the founder of Akava Therapeutics, a startup company commercializing NU-9 (now called AKV9).
The Promise of NU-9: A History of Success
NU-9's journey began about 15 years ago as part of Silverman's quest to find a small molecule that could prevent the buildup of toxic proteins in neurodegenerative diseases. By 2021, it showed promise in animal models of amyotrophic lateral sclerosis (ALS), clearing toxic proteins and restoring health to upper motor neurons. In 2024, it received FDA clearance for human clinical trials for ALS.
Earlier this year, the team demonstrated that NU-9 could effectively treat Alzheimer's disease. The drug was able to clear toxic amyloid beta oligomers in lab-grown brain cells from the hippocampus, a crucial region for learning and memory.
"In both ALS and Alzheimer's disease, cells suffer from toxic protein buildup," says Klein. "NU-9 is rescuing the pathway that saves the cell."
Early Intervention: A Key to Success
To further investigate NU-9's potential, the researchers wanted to see if it could halt the earliest damage in Alzheimer's. They administered NU-9 to a pre-symptomatic mouse model of the disease, giving them a daily oral dose for 60 days.
The results were remarkable. NU-9 significantly reduced early reactive astrogliosis, an inflammatory reaction that often appears long before symptoms emerge. The number of toxic amyloid beta oligomers bound to astrocytes (star-shaped brain cells that protect neurons and control inflammation) also plummeted. Furthermore, an abnormal form of the protein TDP-43, linked to cognitive impairments, sharply decreased.
"These results are stunning," Klein stated. "NU-9 had an outstanding effect on reactive astrogliosis, which is the essence of neuroinflammation and linked to the early stage of the disease." The improvements were seen across multiple brain regions, suggesting a brain-wide anti-inflammatory effect.
A Hidden Culprit: Unmasking the Toxic Subtype
While studying the effects of NU-9, the team discovered a previously unrecognized culprit. Scientists have long considered amyloid beta oligomers more toxic than the larger amyloid beta fibrils that form plaques. However, not all oligomers are the same. The Northwestern scientists identified a uniquely problematic subtype.
"We identified a distinct amyloid beta oligomer subtype that appears inside neurons and on nearby reactive astrocytes very early in the disease," Kranz explained. "It potentially acts as an instigator of early Alzheimer's pathology."
This subtype, called ACU193+ because it's detected by the antibody ACU193, appears early inside stressed neurons. These oligomers then migrate to the surfaces of nearby astrocytes. When ACU193+ oligomers latch onto astrocytes, they may trigger a cascade of inflammation that spreads throughout the brain, long before memory loss begins.
A Potential Prophylaxis: Preventing the Disease
NU-9 targeted and dramatically reduced this specific subtype, suggesting it could be particularly valuable in the earliest stages of Alzheimer's. By reducing this subtype, NU-9 could potentially prevent the activation of astrocytes.
Astrocytes, while serving as the brain's frontline responders, become destructive when pushed into a reactive state. This destructive behavior damages synapses, releases inflammatory molecules, and accelerates neurodegeneration. Stopping this process could be a powerful way to slow the progression of Alzheimer's disease.
Kranz and Silverman compared this strategy to early intervention approaches for preventing cancer and heart disease. Silverman said, "NU-9 could play a similar role. If someone has a biomarker signaling Alzheimer's disease, then they could start taking NU-9 before symptoms appear."
"There are a couple early diagnostic blood tests for Alzheimer's disease in development," Klein added. "The promise of better early diagnostics -- combined with a drug that could stop the disease in its tracks -- is the goal."
What's Next?
The team is currently testing NU-9 in additional Alzheimer's disease models, including an animal model of late-onset disease. They also plan to monitor the animals for a longer period to see if symptoms develop and to examine how early intervention with NU-9 affects memory and neuron health over time.
The implications of this research are profound. Could we be on the cusp of a new era in Alzheimer's treatment? What do you think? Share your thoughts in the comments below! Do you believe that early intervention is the key to combating this disease? Or do you have concerns about potential side effects or long-term impacts? Let's start a conversation!
The study, "Identification of a glia-associated amyloid beta oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU-9," was supported by the National Institute of Health (grant AG061708).
}
